
Propanc Biopharma Receives Nasdaq Bid Price Deficiency Notice
The company plans to appeal to a Nasdaq hearings panel by Oct. 30, which would stay the Nov. 2 delisting.
Propanc Biopharma, Inc. · Nasdaq · Pharmaceutical Preparations

The company plans to appeal to a Nasdaq hearings panel by Oct. 30, which would stay the Nov. 2 delisting.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Delisting notice / failure to meet listing standard
AI summary, unreviewedPropanc Biopharma Receives Nasdaq Delisting Notice for Failing $1.00 Minimum Bid Price, Will Appeal to Hearings Panel